If I was to try to put my finger on one thing that concerned me about BCC, it would be my expectation of what that bar chart of quarterly numbers for "shipped and invoiced" Zoleo units should now look like. I took their previous advice to the market that gave specific info about when the orders received would turn into S&I, and that bar chart should by now show much stronger growth for FY22 Q3 & Q4 and FY23 Q1. So I assume they haven't been able to meet their own S&I targets from around a year ago, when that huge glut of new orders was announced. Those delivered Zoleo units might now be delivering the subscription revenues that we all hoped for, perhaps over the next 6 months, but they are missing. Lastly, at an MC of $16m, it doesn't give them much scope to raise money from the market should they need to do so, which I think is another potential problem BCC. So many of these emerging problems come back to how shareholders value the company, and how illiquid is the stock. But management have really done very little to advertise the stock to investors over the past 12 months, so the SP and sentiment just continues to look very bad.
All IMHO, DYOR
BCC Price at posting:
19.0¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)